Search Results

Learn about the FDA approval of Invokana, a breakthrough in treating diabetic kidney disease and reducing heart failure risk in patients with type 2 diabetes.

Every day is Earth Day at a company that has made sustainable practices a priority for more than 130 years. Take a look at these highly creative recycling programs that have popped up through the decades.

Highlights include four late-breaking XARELTO® (rivaroxaban) abstracts Four INVOKANA® (canagliflozin) abstracts from the pivotal CREDENCE study will also be presented

Analysis shows consistent renal and cardiovascular benefit when treated with INVOKANA® even when patients had moderate to severe renal deficiency INVOKANA® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKD Data announcement comes after recent news of the company’s commercial partnership with Vifor Pharma, leader in nephrology, to jointly commercialize the INVOKANA® DKD indication in the United States

1.3 Million Blood Glucose Monitoring Testing Strips to be Donated to International Diabetes Federation’s Life for a Child in Honor of World Diabetes Day

Dana Pelz was just out of college and about to start a job at Johnson & Johnson when she got stunning news: She had a life-threatening blood disorder. Today, she’s not only thriving—but helping others get a chance at life through Be The Match.